Indaptus Therapeutics Q1 EPS $(0.45) Misses $(0.44) Estimate
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics reported Q1 EPS of $(0.45), missing the consensus estimate of $(0.44) by 2.27%. This represents an 11.76% improvement over last year's Q1 losses of $(0.51) per share.
May 08, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Indaptus Therapeutics reported a slight miss in Q1 EPS, showing improvement over the previous year's losses.
Missing the EPS estimate, even slightly, can lead to negative investor sentiment in the short term, potentially impacting the stock price negatively. However, the improvement over last year's losses may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100